Clinical Trial

An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Study acronym: KEYNOTE-E12
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed in adult patients with advanced solid tumors.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2020-06-19; most recent amendment 2026-03-16.
Status change: Active, Not Recruiting → Recruiting 2026-03-16
Status change: Recruiting → Active, Not Recruiting 2024-12-02
Status change: Not Yet Recruiting → Recruiting 2020-07-02
Trial Details
NCT Number NCT04443088
Lead Sponsor Shenzhen Ionova Life Sciences Co., Ltd.
Collaborators: Merck Sharp & Dohme LLC
Conditions Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma, Solid Tumor, Unspecified, Adult, Tumor, Solid
Enrollment 78 participants
Start Date 2020-06-26
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-18